VANDERBILT UNIVERSITY MEDICAL CENTER MULTIDISCIPLINARY SURGICAL CRITICAL CARE

SURGICAL INTENSIVE CARE UNIT INSULIN TRANSITION PROTOCOL

Purpose: To improve glycemic control when transitioning from a continuous insulin infusion (CII) to subcutaneous insulin and provide guidance on appropriate insulin dosing regimens.

Patient Categories:

-Category 1: Patients with a history of DM <u>OR</u> those requiring insulin infusion of ≥ 3 units/h -Category 2: Patients without a history of diabetes requiring CII < 3 units/h infusion transition to SSI

Transition From IV to SQ Insulin

For Category 1 patients:

- 1. Determine average hourly rate of CII and multiply by 24 to obtain the average insulin requirement for the past 24 hours.
 - Clinical judgment may supersede exact calculation of 24 hour insulin requirements if patients clinical status has rapidly changed or if the patients BG/CII rate has not been stable
- 2. Calculate 70% of the 24h insulin requirement. This will be the total daily dose (TDD) of subcutaneous insulin divided into long and short acting insulin.
 - a. Give 50% of TDD as basal insulin (insulin glargine)
 - i. Basal insulin should be administered 2 hours prior to discontinuation of CII
 - ii. Give regardless of oral intake
 - b. Give 50% of TDD as scheduled short acting insulin in divided doses
 - i. For patients on continuous tube feeds or those not with stable diet (**preferred**):
 - 1. Divide TDD into 4 doses of regular insulin given every 6 hours.
 - 2. If tube feeds are stopped, hold scheduled regular insulin
 - a. Consider starting a 10% dextrose infusion to maintain euglycemia
 - ii. For patients stable on a regular diet (three meals per day):
 - 1. Divide TDD into 3 doses of rapid acting insulin and give before meals
 - 2. Hold if patient is NPO
- 3. Order SQ insulin sliding scale per the SICU protocol to be given with scheduled short acting insulin (same type of insulin and same frequency)

For Category 2 patients:

- Order sliding scale lispro insulin per the SICU protocol in Wiz/HEO
- SSI dose based on a formula calculated as:

[blood glucose (mg/dL)] – 90 15

- SSI adjusted by changing denominator in calculation: range 8-15
 - 0 8 as most restrictive scale and 15 as least restrictive scale

Clinical failure on SQ insulin defined as two consecutive BG readings >250 mcg/dL $\,$

• Results in transition back to CII

| Suggesten starting doses for SQ mount sused | | | | | | | | |
|---|--|---|-----------------------|---|--|---|---------|--|
| | Average hourly rate of IV insulin (CII) | | Dose of basal insulin | | Dose of bolus insulin (short/rapid acting) | | | |
| | 2 units/hour | = | 16 units one daily | + | 4 units every 6 hours or 5 units before each meal (TID) | + | | |
| | 3 units/hour | = | 24 units one daily | + | 6 units every 6 hours or 8 units before each meal (TID) | + | | |
| | 4 units/hour | = | 32 units one daily | + | 8 units every 6 hours or 10 units before each meal (TID) | | | |
| | 5 units/hour | = | 42 units one daily | + | 10 units every 6 hours or 14 units before each meal (TID) | + | Stiding | |
| | 6 units/hour | = | 50 units one daily | + | 12 units every 6 hours or 16 units before each meal (TID) | | Insuin | |
| | 7 units/hour | = | 58 units one daily | + | 14 units every 6 hours or 20 units before each meal (TID) | + | | |
| | 8 units/hour | = | 66 units one daily | + | 16 units every 6 hours or 22 units before each meal (TID) | + | | |

Suggested starting doses for SQ insulin based

TID= three times per day

Example calculation for SSI administration

| Patient's blood aluges | Units of lispro to administer based on denominator of SSI calculation | | | | |
|-------------------------|---|------------|------------|--|--|
| ratient's blood glucose | 8 | 12 | 15 | | |
| 120 mg/dL | 3.75 units | 2.5 units | 2 units | | |
| 170 mg/dL | 10 units | 6.6 units | 5.3 units | | |
| 250 md/dL | 20 units | 13.3 units | 10.6 units | | |

Authors: Michael Kenes, PharmD, BCPS Kelli Rumbaugh PharmD, BCPS

Date last updated: 2/10/2015

References:

- 1. Bode BW, Braithwaite SS, Steed RD, Davidson PC. Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy. Endocr Pract 2004;10(2):71-80.
- 1. Hsia E, Seggelke S, Gibbs J, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab 2012;97(9):3132-7.
- 2. Weant KA, Ladha A. Conversion from continuous insulin infusion to subcutaneous insulin in critically ill patients. Ann Pharmacother 2009;43:629-34.
- 3. Furnary AP, Braithwaite SS. Effects of outcome on in-hospital transition from intravenous insulin infusion to subcutaneous therapy. Am J Cardiol 2006;98(4):557-64.